Nifedipine Tablet, Film Coated, Extended Release
FDA Label NDC 68084-597

49 label sections · Submitted to the FDA by American Health Packaging · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by American Health Packaging for the product Nifedipine (NDC 68084-597). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding description, system components and performance, clinical pharmacology, mechanism of action, pharmacokinetics and metabolism, hemodynamics, electrophysiologic effects, indications and usage, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

Mechanism Of Action

A) Angina
The precise mechanisms by which inhibition of calcium influx relieves angina has not been fully determined, but includes at least the following two mechanisms:

1) Relaxation and Prevention of Coronary Artery Spasm
Nifedipine dilates the main coronary arteries and coronary arterioles, both in normal and ischemic regions, and is a potent inhibitor of coronary artery spasm, whether spontaneous or ergonovine-induced. This property increases myocardial oxygen delivery in patients with coronary artery spasm, and is responsible for the effectiveness of nifedipine in vasospastic (Prinzmetal's or variant) angina. Whether this effect plays any role in classical angina is not clear, but studies of exercise tolerance have not shown an increase in the maximum exercise rate-pressure product, a widely accepted measure of oxygen utilization. This suggests that, in general, relief of spasm or dilation of coronary arteries is not an important factor in classical angina.

2) Reduction of Oxygen Utilization
Nifedipine regularly reduces arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing the total peripheral vascular resistance (afterload) against which the heart works. This unloading of the heart reduces myocardial energy consumption and oxygen requirements, and probably accounts for the effectiveness of nifedipine in chronic stable angina.

B) Hypertension
The mechanism by which nifedipine reduces arterial blood pressure involves peripheral arterial vasodilatation and the resulting reduction in peripheral vascular resistance. The increased peripheral vascular resistance that is an underlying cause of hypertension results from an increase in active tension in the vascular smooth muscle. Studies have demonstrated that the increase in active tension reflects an increase in cytosolic free calcium.

Nifedipine is a peripheral arterial vasodilator which acts directly on vascular smooth muscle. The binding of nifedipine to voltage-dependent and possibly receptor-operated channels in vascular smooth muscle results in an inhibition of calcium influx through these channels. Stores of intracellular calcium in vascular smooth muscle are limited and thus dependent upon the influx of extracellular calcium for contraction to occur. The reduction in calcium influx by nifedipine causes arterial vasodilation and decreased peripheral vascular resistance which results in reduced arterial blood pressure.

General-Hypotension

Because nifedipine decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of nifedipine is suggested. Close observation is especially recommended for patients already taking medications that are known to lower blood pressure. (See WARNINGS).

Peripheral Edema: Mild to moderate peripheral edema occurs in a dose dependent manner with an incidence ranging from approximately 10% to about 30% at the highest dose studied (180 mg). It is a localized phenomenon thought to be associated with vasodilation of dependent arterioles and small blood vessels and not due to left ventricular dysfunction or generalized fluid retention. With patients whose angina or hypertension is complicated by congestive heart failure, care should be taken to differentiate this peripheral edema from the effects of increasing left ventricular dysfunction.

Lactation:

Nifedipine is transferred through breast milk. Nifedipine Extended-release Tablets should be used during breast-feeding only if the potential benefit justifies the potential risk.

Packaging Information

American Health Packaging unit dose blisters (see How Supplied section) contain drug product from Lannett Company, Inc. as follows:
(30 mg / 50 UD) NDC 68084-597-65 packaged from NDC 62175-260
(30 mg / 100 UD) NDC 68084-597-01 packaged from NDC 62175-260
(60 mg / 50 UD) NDC 68084-598-65 packaged from NDC 62175-261
(60 mg / 100 UD) NDC 68084-598-01 packaged from NDC 62175-261
(90 mg / 30 UD) NDC 68084-603-21 packaged from NDC 62175-262
(90 mg / 50 UD) NDC 68084-603-65 packaged from NDC 62175-262

Distributed by:
American Health Packaging
Columbus, OH 43217

8259701/1024(F)

Package/Label Display Panel – Carton – 30 Mg – 50 Ud

NDC 68084- 597-65

NIFEdipine
Extended-release Tablets, USP

30 mg*

50 Tablets (5 x 10)                 Rx Only

*Each Tablet Contains:
33 mg nifedipine to deliver a 30 mg dose.

Usual Dosage: See full prescribing information.

Store at 20° to 25°C (68° to 77°F); excursions permitted between
15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Protect from moisture, humidity, and light.

FOR YOUR PROTECTION: Do not use if blister is torn or broken.

The drug product contained in this package is from
NDC # 62175-260, Lannett Company, Inc.

Distributed by: American Health Packaging, Columbus, Ohio 43217

059765
0259765/0824

Package/Label Display Panel – Blister – 30 Mg

NIFEdipine Extended
release Tablet, USP

30 mg

Package/Label Display Panel – Carton – 60 Mg – 50 Ud

NDC 68084- 598-65

NIFEdipine
Extended-release Tablets, USP

60 mg*

50 Tablets (5 x 10)                 Rx Only

*Each Tablet Contains:
66 mg nifedipine to deliver a 60 mg dose.

Usual Dosage: See full prescribing information.

Store at 20° to 25°C (68° to 77°F); excursions permitted between
15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Protect from moisture, humidity, and light.

FOR YOUR PROTECTION: Do not use if blister is torn or broken.

The drug product contained in this package is from
NDC # 62175-261, Lannett Company, Inc.

Distributed by: American Health Packaging, Columbus, Ohio 43217

059865
0259865/0824

Package/Label Display Panel – Blister – 60 Mg

Nifedipine Extended-
release Tablet, USP

60 mg

Package/Label Display Panel – Carton – 90 Mg – 50 Ud

NDC 68084- 603-65

NIFEdipine
Extended-release Tablets, USP

90 mg*

50 Tablets (5 x 10)                 Rx Only

*Each Tablet Contains:
99 mg nifedipine to deliver a 90 mg dose.

Usual Dosage: See full prescribing information.

Store at 20° to 25°C (68° to 77°F); excursions
permitted between 15° to 30°C (59° to 86°F) [see
USP Controlled Room Temperature].
Protect from moisture, humidity, and light.

FOR YOUR PROTECTION:
Do not use if blister is torn or broken.

The drug product contained in this package is
from NDC # 62175-262, Lannett Company, Inc.

Distributed by: American Health Packaging,
Columbus, Ohio 43217

060365
0260365/0824

Package/Label Display Panel – Blister – 90 Mg

NIFEdipine
Extended-release
Tablet, USP

90 mg

* Please review the disclaimer below.